StemCyte-KY announced on March 4 the signing of a Memorandum of Understanding (MOU) with a major international medical group in China. The partnership targets the licensing and commercialization of REGENECYTE®, its proprietary umbilical cord blood cell therapy, specifically leveraging the policy advantages of the Hainan Boao Lecheng International Medical Tourism Pilot Zone.

• RWD Strategy: By utilizing Hainan’s "Early Access" policy for urgent clinical needs and its Real-World Data (RWD) application mechanism, StemCyte aims to bypass traditional, lengthy trial timelines. This "Sales and Registration Parallel" model allows for immediate clinical use while simultaneously pursuing formal NMPA drug approval.
• Capital Market Milestone: To support this global commercial push, StemCyte confirmed it is on track for its primary listing on the Taiwan Stock Exchange, scheduled for Q2 2026.

Resource: 永笙-KY登陸細胞治療市場，推進REGENECYTE授權合作加速商化